Egle Kvedaraite, Magda Lourda, Johannes Bastiaan Munting, Matthias Papo, Martin Jädersten, Yoko Shioda, Kenichi Sakamoto, Daniel Martín Muñoz, Panagiotis Andriopoulos, Francesco Pegoraro, Evaldas Laurencikas, Ingrid Kühnle, Joakim Wille, Leonie Naeije, Helena Olkinuora, Indranil Sinha, Daniel W Hagey, Selma Olsson-Åkefeldt, Fleur Cohen-Aubart, Gustaf Österlundh, Mattias Svensson, Ahmed Idbaih, Fredrik Piehl, Kaj Blennow, Henrik Zetterberg, Tatiana Greenwood von Bahr, Désirée Gavhed, Akira Morimoto, Julien Haroche, Jan-Inge Henter
Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), yet its underlying biology and reliable biomarkers remain poorly defined. The aim of this study was to (1) gain insight into neuroimmunological mechanisms governing ND and (2) assess the clinical value of established and novel biomarkers for ND-LCH. We applied targeted proteomics and neurofilament light chain (NFL) assays to cerebrospinal fluid (CSF) and plasma from LCH patients with and without ND, with control cohorts. ND-LCH exhibited a distinct CSF proteomic profile characterized by increased decoy receptors, including interleukin-1 receptor type 2 (IL-1RT2), macrophage activation markers, and cytotoxic and immunoregulatory proteins. CSF IL-1RT2 showed higher specificity for ND-LCH than CSF NFL (0.99 [0.99-1.0] vs. 0.88 [0.80-0.96]) and tracked longitudinal disease changes. Plasma analyses revealed a complementary immune signature in which NFL correlated with CSF markers, including IL-1RT2, and distinguished ND-LCH from controls. In independent plasma NFL cohorts from France and Japan, elevated levels were confirmed in adults with histiocytosis-associated ND. These findings define a neuroinflammatory signature of ND-LCH and identify IL-1RT2 as a novel candidate biomarker for diagnosis and monitoring.